A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes
Seasonal influenza vaccines offer little protection against pandemic influenza virus strains. It is difficult to create effective prepandemic vaccines because it is uncertain which influenza virus subtype will cause the next pandemic. In this work, we developed a nucleoside-modified messenger RNA (mRNA)-lipid nanoparticle vaccine encoding hemagglutinin antigens from all 20 known influenza A virus subtypes and influenza B virus lineages. This multivalent vaccine elicited high levels of cross-reactive and subtype-specific antibodies in mice and ferrets that reacted to all 20 encoded antigens. Vaccination protected mice and ferrets challenged with matched and mismatched viral strains, and this protection was at least partially dependent on antibodies. Our studies indicate that mRNA vaccines can provide protection against antigenically variable viruses by simultaneously inducing antibodies against multiple antigens.
| Errataetall: |
CommentIn: Science. 2022 Nov 25;378(6622):827-828. - PMID 36423290 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:378 |
|---|---|
| Enthalten in: |
Science (New York, N.Y.) - 378(2022), 6622 vom: 25. Nov., Seite 899-904 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arevalo, Claudia P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Hemagglutinin Glycoproteins, Influenza Virus |
|---|
| Anmerkungen: |
Date Completed 30.11.2022 Date Revised 10.02.2024 published: Print-Electronic CommentIn: Science. 2022 Nov 25;378(6622):827-828. - PMID 36423290 Citation Status MEDLINE |
|---|
| doi: |
10.1126/science.abm0271 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349363463 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349363463 | ||
| 003 | DE-627 | ||
| 005 | 20240210232450.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/science.abm0271 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM349363463 | ||
| 035 | |a (NLM)36423275 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arevalo, Claudia P |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.11.2022 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Science. 2022 Nov 25;378(6622):827-828. - PMID 36423290 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Seasonal influenza vaccines offer little protection against pandemic influenza virus strains. It is difficult to create effective prepandemic vaccines because it is uncertain which influenza virus subtype will cause the next pandemic. In this work, we developed a nucleoside-modified messenger RNA (mRNA)-lipid nanoparticle vaccine encoding hemagglutinin antigens from all 20 known influenza A virus subtypes and influenza B virus lineages. This multivalent vaccine elicited high levels of cross-reactive and subtype-specific antibodies in mice and ferrets that reacted to all 20 encoded antigens. Vaccination protected mice and ferrets challenged with matched and mismatched viral strains, and this protection was at least partially dependent on antibodies. Our studies indicate that mRNA vaccines can provide protection against antigenically variable viruses by simultaneously inducing antibodies against multiple antigens | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Lipid Nanoparticles |2 NLM | |
| 650 | 7 | |a Nucleosides |2 NLM | |
| 650 | 7 | |a Vaccines, Combined |2 NLM | |
| 650 | 7 | |a mRNA Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Synthetic |2 NLM | |
| 650 | 7 | |a Hemagglutinin Glycoproteins, Influenza Virus |2 NLM | |
| 700 | 1 | |a Bolton, Marcus J |e verfasserin |4 aut | |
| 700 | 1 | |a Le Sage, Valerie |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Naiqing |e verfasserin |4 aut | |
| 700 | 1 | |a Furey, Colleen |e verfasserin |4 aut | |
| 700 | 1 | |a Muramatsu, Hiromi |e verfasserin |4 aut | |
| 700 | 1 | |a Alameh, Mohamad-Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a Pardi, Norbert |e verfasserin |4 aut | |
| 700 | 1 | |a Drapeau, Elizabeth M |e verfasserin |4 aut | |
| 700 | 1 | |a Parkhouse, Kaela |e verfasserin |4 aut | |
| 700 | 1 | |a Garretson, Tyler |e verfasserin |4 aut | |
| 700 | 1 | |a Morris, Jeffrey S |e verfasserin |4 aut | |
| 700 | 1 | |a Moncla, Louise H |e verfasserin |4 aut | |
| 700 | 1 | |a Tam, Ying K |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Steven H Y |e verfasserin |4 aut | |
| 700 | 1 | |a Lakdawala, Seema S |e verfasserin |4 aut | |
| 700 | 1 | |a Weissman, Drew |e verfasserin |4 aut | |
| 700 | 1 | |a Hensley, Scott E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science (New York, N.Y.) |d 1880 |g 378(2022), 6622 vom: 25. Nov., Seite 899-904 |w (DE-627)NLM000023450 |x 1095-9203 |7 nnns |
| 773 | 1 | 8 | |g volume:378 |g year:2022 |g number:6622 |g day:25 |g month:11 |g pages:899-904 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/science.abm0271 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 378 |j 2022 |e 6622 |b 25 |c 11 |h 899-904 | ||